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Abstract
Summary High bone mineral density on routine dual energy
X-ray absorptiometry (DXA) may indicate an underlying
skeletal dysplasia. Two hundred fifty-eight individuals with
unexplained high bone mass (HBM), 236 relatives (41% with
HBM) and 58 spouses were studied. Cases could not float, had
mandible enlargement, extra bone, broad frames, larger shoe
sizes and increased body mass index (BMI). HBM cases may
harbour an underlying genetic disorder.
Introduction High bone mineral density is a sporadic
incidental finding on routine DXA scanning of apparently
asymptomatic individuals. Such individuals may have an
underlying skeletal dysplasia, as seen in LRP5 mutations.
We aimed to characterize unexplained HBM and determine
the potential for an underlying skeletal dysplasia.
Methods Two hundred fifty-eight individuals with unex-
plained HBM (defined as L1 Z-score≥+3.2 plus total hip Z-
score≥+1.2, or total hip Z-score≥+3.2) were recruited from 15
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UK centres, by screening 335,115 DXA scans. Unexplained
HBM affected 0.181% of DXA scans. Next 236 relatives were
recruited of whom 94 (41%) had HBM (defined as L1 Z-
score + total hip Z-score≥+3.2). Fifty-eight spouses were
also recruited together with the unaffected relatives as
controls. Phenotypes of cases and controls, obtained from
clinical assessment, were compared using random-effects
linear and logistic regression models, clustered by family,
adjusted for confounders, including age and sex.
Results Individuals with unexplained HBM had an excess
of sinking when swimming (7.11 [3.65, 13.84], p<0.001;
adjusted odds ratio with 95% confidence interval shown),
mandible enlargement (4.16 [2.34, 7.39], p<0.001), extra
bone at tendon/ligament insertions (2.07 [1.13, 3.78], p=
0.018) and broad frame (3.55 [2.12, 5.95], p<0.001). HBM
cases also had a larger shoe size (mean difference 0.4 [0.1,
0.7] UK sizes, p=0.009) and increased BMI (mean
difference 2.2 [1.3, 3.1]kg/m2, p<0.001).
Conclusion Individuals with unexplained HBM have an
excess of clinical characteristics associated with skeletal
dysplasia and their relatives are commonly affected,
suggesting many may harbour an underlying genetic
disorder affecting bone mass.
Keywords Bone mineral density . DXA . High bone mass .
Negative buoyancy . Skeletal dysplasia
Introduction
Routine dual energy X-ray absorptiometry (DXA) scanning
sporadically identifies individuals with extremely high bone
mineral density (BMD) values, which are not always
explained by artefactual causes such as osteoarthritis (OA),
the syndesmophytes of ankylosing spondylitis, or surgically
implanted metalwork. Paget’s disease, certain malignancies
and rare conditions such as myelofibrosis and hepatitis C
osteosclerosis can also raise BMD values [1–4]. Furthermore,
several rare causes of generalized high bone mass (HBM)
have been described, including skeletal dysplasias, which are
frequently associated with complications secondary to
skeletal overgrowth due to increased osteoblast or decreased
osteoclast activity [5–7]. However, it is our clinical impres-
sion that the great majority of individuals with HBM lack
significant pathological sequelae and have no identifiable
cause, although, as far as we are aware, this question has not
been systematically studied.
Individuals with unexplained HBM may represent one
extreme tail of a normal population distribution of BMD
reflecting BMD as a polygenic trait, with many genes each
exerting a small effect upon the phenotype. Alternatively,
unexplained HBM may reflect an underlying skeletal
dysplasia, caused by as yet unidentified single gene
mutations. Identification of the monogenic and/or polygenic
basis of HBM may provide new and important insights into
the molecular mechanisms responsible for bone mass regula-
tion. Whilst hyperostotic and sclerosing skeletal dysplasias
can be associated with obvious pathological sequelae related
to bone overgrowth, such as cranial nerve palsies [8–11] or
impaired haematopoiesis [7], these complications may be
relatively rare in those with incidental unexplained HBM.
For example, an asymptomatic skeletal dysplasia has
previously been reported in some individuals, such as those
associated with LRP5 mutations in whom pathological
features are less commonly observed [12–15]. Nevertheless,
case reports have suggested individuals with LRP5 mutations
have subtle clinical features of a mild skeletal dysplasia such
as difficulty in floating while swimming or mandible
enlargement [13, 14, 16].
In this study, we aimed to determine the prevalence of
unexplained HBM amongst a DXA population. To achieve
this, we used resources available within the UK National
Health Service (NHS), to systematically search databases of
DXA scan results across a series of UK centres, for individuals
with raised BMD, from whom those with unexplained HBM
could then be identified. Amongst the first-degree relatives of
individuals identified as having unexplained HBM, we aimed
to establish whether BMD was bi-modally distributed in
keeping with a monogenic skeletal dysplasia such as that
caused by activating mutations of LRP5. To further assess
whether individuals with unexplained HBM have an under-
lying skeletal dysplasia, we evaluated clinical features
associated with sclerosing and/or hyperostotic skeletal dys-
plasias, such as mandible enlargement, nerve compression,
increased skeletal size, osseous tori and impaired buoyancy.
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Methods
HBM prevalence on DXA databases
DXA databases were initially searched for individuals with a
BMD T- or Z-score≥+4 at any site within the lumbar spine or
hip, at 13 NHS trusts in England andWales (Hologic scanners
at Bath, North Bristol, Cambridge, Cardiff, St George’s
London, Gwent, Ipswich, Oxford, Sheffield; Lunar scanners
at Birmingham, South Bristol, Eastbourne, Hull). A further
two centres contributed similar individuals identified prospec-
tively (Hologic: Guy’s London, Yeovil). Previous case studies
of LRP5 HBM used Z-score thresholds to define HBM [13];
however, as Hologic DXA scanner databases store T- but not
Z-scores, our search was of T- and/or Z-score≥+4. All DXA
images were visually inspected by clinicians or clinical
scientists trained in the interpretation of DXA, and those
with identifiable explanations for a high BMD value, such as
osteoarthritis, were excluded. Evidence of significant osteo-
arthritis on lumbar DXA scans is common. To reduce
contamination of our remaining DXA scans by more
moderate osteoarthritis, we aimed to refine our case definition
based upon restriction to specific lumbar verterba(e). At our
largest centre, 562 scans with T-/Z-score≥+4 were graded for
OA severity by Kellgren and Lawrence scores and examined
in relation to BMD at lumbar vertebral levels [17, 18]. In
contrast to other lumbar vertebrae, L1 Z-score was not
associated with the presence of OA, reflecting the recognised
pattern of progressive OA changes seen in descending
sequential lumbar vertebrae [19], nor did total hip Z-score
reflect lumbar spine OA. A generalized HBM trait would be
expected to affect both spine and hip BMD, though not
necessary to the same extent. Hence, we refined our
definition of HBM index cases as having either (a) L1 Z-
score of ≥+3.2 plus a total hip Z-score no lower than +1.2 or
(b) a total hip Z-score≥+3.2 plus a L1 Z-score no lower
than +1.2. A threshold of +3.2 was in keeping with the only
published precedent for identifying HBM previously
described using DXA [13] and most appropriately differen-
tiated generalized HBM from artefact. Z rather than
T-score was used to limit age bias. A standard deviation of
+3.2 would be expected to identify a tail of 0.069% of a
normal distribution [20]. Since the prevalence of HBM on
DXA databases is likely to be influenced by motivations for
DXA referral, we examined the latter in a subgroup of 22%
of scans at the largest centre in Hull, where referral
indication was recorded in an adjunctive database linked to
their Lunar DXA database.
The distribution of BMD amongst relatives
Surviving index cases, identified from DXA database
searches described above, who were still resident in the
area, were invited by letter and follow-up telephone call to
attend their local DXA centre for clinical assessment
(described below) and in order to construct family
pedigrees. Elderly, immobile individuals were offered home
visits to limit participation bias (n=2). For those with
difficulties in attending a local DXA centre, telephone
interviews were offered (n=37). Index cases were asked to
pass on study invitations to their first-degree relatives and
spouse/partner(s). These relatives and spouses were invited
only once, and non-responders were not followed up.
Relatives/spouses with HBM were in turn asked to pass
on study invitations to their (previously uninvited) first-
degree relatives and spouses. Recruitment ran from 1 July
2005 until 30 April 2010. Written informed consent was
collected for all in line with the Declaration of Helsinki
[21]. Participants were excluded if under 18 years of age,
pregnant or unable to provide written informed consent
for any reason. This study was approved by the Bath
Multi-centre Research Ethics Committee (REC) and at
each NHS Local REC.
Clinical assessment of HBM characteristics
Those index cases, relatives and spouses able to attend their
local centre, were clinically assessed by a doctor or research
nurse using a standardised structured history and examina-
tion questionnaire assessing features previously reported in
individuals with sclerosing and/or hyperostotic skeletal
dysplasias. Reported operations were coded using OPCS4
(Office of Population, Censuses and Surveys Classification
of Surgical Operations and Procedures [4th revision]). Joint
replacement included OPCS4 codes W37–W58 inclusive.
DXA scans were performed for relatives and spouses after
clinical assessment using local Hologic Inc. (Bedford, MA,
USA) and GE Lunar Inc. (Madison, WI, USA) DXA
systems using each manufacturer’s standard scan and
positioning protocols, and DXA weight and routine height
measurements were recorded. Manufacturer reference data
were used for T- and Z-score calculations (Hologic
NHANES and GE Lunar UK reference populations),
matched for gender and ethnicity (weight adjustment
disabled for GE Lunar scans). BMD was standardised
using established formulae [22, 23]. Body mass index
(BMI) was calculated as weight (kilograms)/height (square
metres). Serum corrected calcium, phosphate, alkaline
phosphatase and a full blood count were analysed at the
coordinating centre laboratory (United Bristol Healthcare
NHS Trust). Samples delayed in transit for more than 48 h
were excluded to omit measurement error from haemolysis.
All participants had plain radiographs of AP hand and
knees, plus AP lumbar spine and pelvis if aged over
40 years. DNAwas also collected for future genetic studies,
and permission sought for future follow-up. Clinical
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assessments occurred during a single visit to maximize
uniformity.
Statistical analysis
Descriptive statistics for index cases, relatives and spouses
are presented as mean (95% confidence interval (CI)) for
continuous and count (percentages) for categorical data and
compared using linear regression and chi-squared tests,
respectively. Age and gender were considered a priori
confounders, oestrogen treatment and menopausal status as
potential confounders in the analysis of clinical character-
istics. To enable confounder adjustment for categorical
variables, index cases, relatives and spouses were re-
categorised as cases or controls, to permit analysis by
logistic regression, using two different strategies: (a)
Relatives were divided into cases and controls based upon
an arbitrary threshold identified after inspection of BMD
distributions (the HBM definition for spouses was as for
index cases) and (b) all relatives were combined with
unaffected spouses to act as controls. Random-effects
models were used to allow for the lack of statistical
independence due to within-family clustering of environ-
mental factors and shared genotypes. Crude and adjusted
mean differences and cluster-specific odds ratios (OR), with
95% CIs, are presented. No family had >10 members.
When rho, the measure of within-family correlation, was
large (>0.25), OR reliability was checked by refitting the
model at different quadrature points and ensuring the
coefficient relative differences were <0.01. Data were
managed using Microsoft Access (data entry checks; error
rate <0.12%) and analysed using Stata release 11 statistical
software (StataCorp, College Station, TX, USA).
Results
HBM prevalence on DXA databases
In total, 335,115 historical DXA scans were screened across
13 databases, collected over a combined total of 110.2 years,
the earliest from 1992. DXA scans of all those with T- or Z-
scores≥+4 from ten centres were inspected by both CG and
JT; 49.4% were considered to have artefactually raised
BMD due to degenerative changes (Table 1); 9.7% of DXA
scans had evidence of other artefacts to explain their high
BMD or were unverifiable. Of the remaining cases, 5.8%
did not meet our Z-score threshold for defining HBM. After
screening DXA databases at the other three NHS centres,
local investigators identified a further 86 HBM cases as
meeting our entry criteria. The final prevalence of HBM is
shown in Table 2. When results from searching Hologic and
Lunar databases were combined, the overall prevalence of
HBM was 0.181%. Indication for DXA referral was
examined in a subgroup of 22% of scans at the largest
centre in Hull (Online Resource Table 1). The most
common indication was a suspicion of osteoporosis based
upon height loss or low trauma fracture (28.8%), which
also accounted for 35.3% of indications for DXAs which
were found to have a T-/Z-score≥+4. Treatment monitoring
prompted 17.1% of overall referrals but only accounted for
4.8% of referrals for DXA in individuals found to have
high BMD.
Descriptive analyses of HBM index cases and their
relatives and spouses
We recruited 258 (41%) of HBM cases into our subsequent
study of the detailed phenotype of HBM, identified from a
total of 15 sites in England and Wales (Fig. 1). These cases
Table 1 Causes of a raised T- or Z-score of +4 or greater on DXA
scans screened and inspected from ten NHS centres
Causes of T-/Z-score≥+4 Number Percent
High bone massa 520 35.1
Degenerative disease/osteoarthritis/scoliosis 732 49.4
Generalized sclerosis but below threshold
to qualify as index casea
86 5.8
Surgical metalwork 21 1.4
Paget’s disease 21 1.4
Artefact, cause undetermined 19 1.3
Metastatic disease 16 1.1
Ankylosing spondylitis 15 1.0
Abnormal femoral head, cause unknown 12 0.8
Focal sclerosis, cause uncertain 8 0.5
Girdlestone’s hip 5 0.3
Vertebral fracture 3 0.2
Autosomal recessive osteopetrosisb 2 0.1
X-linked hyphosphotaemic ricketsb 2 0.1
Morbid obesity (BMI>40) 2 0.1
Pycnodysostosisb 1 0.1
Hepatitis C osteosclerosis 1 0.1
Gaucher’s diseasec 1 0.1
Fluorosis 1 0.1
Unknown 14 0.9
Total 1,482 100.0
DXA dual X-ray energy absorptiometry, NHS National Health Service,
BMI body mass index
a
HBMdefined as (a) L1 Z-score of ≥+3.2 plus total hip Z-score no lower than
+1.2, or (b) total hip Z-score≥+3.2 plus L1 Z-score no lower than +1.2
b
Established diagnoses recorded on linked hospital records
c
Considered as causing high lumbar BMD. BMD highest at L1 then
gradually reduced in sequential descending lumbar vertebrae. Hip BMD
was low. Findings likely to be explained by the high glycolipid load within
the overlying enlarged spleen
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were similar to those not recruited, except non-participants
were shorter and had slightly lower left hip sBMD (Online
Resource Table 2). Eight hundred ninety-three relatives
were invited to participate, of whom 236 (26.4%) were
recruited. Two hundred seventeen spouses/partners were
invited to participate, of whom 61 (28.1%) were recruited;
two individuals invited two partners (Fig. 1). Of the 258
HBM index cases recruited, 103 (39.9%) contributed one or
more relatives into the study; 94.6% of index cases, 86.6%
relatives and 93.3% spouses were able to be examined.
Participants ranged in age from 18 to 90 years, and all but
three were Caucasian.
The majority of index cases were female and spouses
male, whilst relatives showed a more even gender distribu-
tion (Table 3). Most female index cases and spouses were
post-menopausal, whereas just over half of female relatives
had passed the menopause because relatives were generally
younger than index cases and spouses. Despite their similar
proportions of post-menopausal females, a greater propor-
tion of index cases had taken oestrogen replacement
compared to spouses. Index cases were shorter than
relatives and spouses, likely reflecting differences in gender
distribution. BMI was higher amongst index cases com-
pared to relatives and spouses.
BMD Z-scores showed a Gaussian rather than a bi-modal
distribution in all three groups (Fig. 2). As expected, mean Z-
scores of the total hip and L1, both separately and combined,
were considerably higher in HBM cases than spouses,
whereas mean values in relatives were higher than spouses
Table 2 Thirteen NHS centre Hologic and Lunar DXA databases
were screened in order to identify the high bone mass cases;
prevalence of unexplained high bone mass amongst a DXA population
Hologic DXA databasesa
Total scanning period for all Hologic DXAs screened (years) 74.40
Total number of Hologic DXA scans screened across all sites 204,886
Mean number of scans per year per centre 2,753.9
Prevalence of T-/Z-score≥+4 amongst DXA population (%) 0.419
Prevalence of HBM amongst DXA population (%)c 0.161
LUNAR DXA databasesb
Total scanning period for all Lunar DXAs screened (years) 35.82
Total number of individuals screened across all Lunar sites 130,229
Mean number of individuals scanned per year per centre 3,635.4
Prevalence of T-/Z-score≥+4 amongst DXA population (%) 0.563
Prevalence of HBM amongst DXA population (%)c 0.213
Lunar DXA databases store number of individuals scanned, whilst
Hologic store number of scans performed, thus not accounting for
repeat scans per individual; hence, results are stratified by DXA
manufacturer
DXA dual X-ray energy absorptiometry, NHS National Health Service,
HBM high bone mass
a
Hologic at Bath, North Bristol, Cambridge, Cardiff, St George’s, Gwent,
Ipswich, Oxford, Sheffield
b
Lunar at Birmingham, South Bristol, Eastbourne, Hull
c
HBM defined as (a) L1 Z-score of ≥+3.2 plus total hip Z-score no
lower than +1.2, or (b) total hip Z-score≥+3.2 plus L1 Z-score no
lower than +1.2
13 UK DXA databases screened 
for T &/or Z score≥+4 (n=335,115) 
606 Unexplained HBM cases identified 
533 Unexplained HBM cases invited
96 not invited: 
  35 had died 
  47 no UK contact address 
  14 study recruitment closed 
266 not recruited: 
  96 declined 
  155 no response 
  15 logistical limitations 
9 responded but disclosed 
explanations for HBM eg. 
Paget’s disease, Ankylosing 
Spondylitis, X-Linked 
Hypophosphotaemic rickets
61 Spouses/partners recruited 236 Relatives recruited 
142 Unaffected 
Relatives 
58 Unaffected 
Spouses 
258 HBM Index cases recruited 
3 HBM Spouses 94 HBM Relatives 
23 unexplained HBM cases 
arose during routine clinical 
practice at 2 further UK 
centres 
Fig. 1 Flow diagram summariz-
ing the recruitment process of
HBM index cases and then their
relatives and spouses. UK United
Kingdom, DXA dual X-ray
energy absorptiometry, HBM
high bone mass. All participants
with HBM were pooled (258
index cases, 94 relatives, 3
spouses) shown in octagonal
boxes filled with grey dots. All
participants unaffected by HBM
were pooled (142 unaffected
relatives and 58 unaffected
spouses) shown in hatched
boxes. Two centres recruited
prospectively on a case-by-case
when qualifying DXA scans
arose as part of routine clinical
practice
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but lower than HBM cases (Table 3). This was despite Z-
scores in spouses being elevated in comparison with the DXA
scanner manufacturer’s reference population. Although L1
area initially appeared greater in spouses compared to index
cases, following adjustment for age at time of DXA, gender,
years since menopause, oestrogen replacement use, height and
weight, L1 area was greater in index cases than spouses, with
relatives showing intermediate results. Similar findings were
seen irrespective of whether results were restricted to centres
with Hologic or Lunar scanners (data not shown).
Table 3 Descriptive characteristics of recruited high bone mass index cases, their relatives and spouses/partners
n (555) Index n (%; n=261) Relative n (%; n=236) Spouse n (%; n=58) χ2 p value
Female 555 206 (78.9) 143 (60.6) 16 (27.6) <0.001
Post-menopausal 351 180 (89.6) 74 (54.8) 12 (80.0) <0.001
Oestrogen replacementa 321 110 (60.1) 28 (22.2) 5 (41.7) <0.001
Caucasian 555 258 (98.9) 236 (100) 58 (100) 0.758
n (555) Index mean
(95% CI; n=261)
Relative mean
(95% CI; n=236)
Spouse mean
(95% CI; n=58)
Unadjusted
p value
Anthropometric characteristics
Age (years)b 555 64.5 (62.8, 66.2) 51.7 (49.9, 53.4) 63.3 (59.8, 66.7) <0.001
Height (cm)c 555 166.3 (165.1, 167.4) 169.5 (168.2, 170.8) 172.5 (170.2, 174.8) <0.001
Weight (kg)c 555 85.5 (83.3, 87.6) 82.6 (80.0, 85.2) 85.6 (81.4, 89.8) 0.118
BMI (kg/m2)c 555 31.0 (30.2, 31.7) 28.8 (27.9, 29.7) 29.0 (27.7, 30.4) <0.001
DXA characteristics
Sum L1 and total hip Z-scoresd 555 7.58 (7.30, 7.87) 2.62 (2.32, 2.93) 1.40 (0.81, 2.00) <0.001
Total hip Z-scored 534 3.26 (3.10, 3.41) 1.25 (1.07, 1.42) 0.66 (0.36, 0.96) <0.001
L1 Z-score 547 4.29 (4.10, 4.48) 1.38 (1.19, 1.58) 0.81 (0.42, 1.20) <0.001
L1 area (cm2) 542 14.09 (13.81, 14.36) 13.90 (13.59, 14.22) 14.77 (14.23, 15.30) 0.013
L1 area (cm2)e 542 16.18 (15.33, 17.04)e 15.46 (14.72, 16.20)e 15.26 (14.37, 16.16)e <0.001e
BMI body mass index, L1 first lumbar vertebra, DXA dual X-ray energy absorptiometry
a
Previous or current use of oestrogen replacement therapy
b
Recorded at time when recruited into study and clinical data obtained
c
Recorded at time of first DXA scan
d
When dual femur scanning the highest of right and left total hip Z-score was used. No evidence of interaction by DXA scanner type (Hologic/Lunar) for
any DXA parameters was detected
e
Adjusted for age at time of DXA, gender, years since menopause and oestrogen replacement use, weight and height
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Index cases, relatives and
spouses were 7.58 (7.30, 7.87),
2.62 (2.32, 2.93) and 1.40
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HBM amongst relatives. If both
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Clinical characteristics associated with unexplained HBM
To analyse clinical characteristics associated with HBM
using logistic regression (which enabled adjustment for
confounders), relatives were assigned as cases or controls
based upon the Z-score +3.2 threshold (see Fig. 2). When
comparing BMD between HBM cases (258 index, 94
affected relatives and three affected spouses) and controls
(142 unaffected relatives and 58 unaffected spouses)
categorised in this way, HBM cases had greater summed
L1 and total hip Z-scores than controls, 6.98 (6.76, 7.20)
vs. 1.04 (0.74, 1.35), p<0.001. Cases were older (mean
difference [95% CI] 7.7 [5.2, 10.3]years), more often
female (272 [76.6%] vs. 93 [46.5%]), and women were
more often post-menopausal (218 [82.9%] vs. 48 [54.5%]),
with a history of oestrogen replacement (128 [52.7%] vs.
15 [19.2%]), p<0.001 for all. After adjusting for these
differences, HBM cases had a greater mean BMI than
controls (2.2 [1.3, 3.1]kg/m2, p<0.001). HBM cases had
increased odds of an enlarged mandible (four HBM cases
having prognathism), a broad frame, misshapen or extra
bone at the site of tendon and/or ligament insertions,
together with a larger shoe size (adjusted mean difference
0.4 of a UK size; Table 4). Whilst there was no difference
in the reporting of dental overcrowding, there was a trend
towards increased odds of reporting a history of structural
oral/dental abnormalities amongst HBM cases. The odds of
reporting visual or auditory problems, hearing aid use or
abnormal vision or hearing being found on examination
were similar amongst cases and controls. Equally, the odds
of reporting spinal stenosis, or an operation for spinal
stenosis, were similar amongst cases and controls (adjusted
OR 0.98 [0.39, 2.45], p=0.959, adjusted for gender and
age). Similarly the odds of cranial nerve palsy were no
higher amongst HBM cases compared with controls
(adjusted OR 1.38 [0.51, 3.70], p=0.522). There was a
weak trend towards increased reporting of carpal tunnel
syndrome amongst HBM cases. Renal calculi and osteo-
myelitis were no more commonly reported amongst cases
than controls and were infrequent.
Interestingly, HBM cases had increased odds of report-
ing sinking when trying to swim (Table 4). Further
adjustment for body weight, height and history of chronic
obstructive pulmonary disease, asthma and smoking (as
proxies for lung capacity) did not materially affect this
association. Whilst fracture history was no different
between cases and controls, HBM cases had reduced odds
of reporting a family history of fracture. HBM cases were
more likely to report current or previous experience of pain
in their mandible, skull/head (including self-reported
migraine) and limb bones in general. Unadjusted results
suggested increased odds of joint pain in cases compared
with controls; however, this was not apparent after
adjustment. HBM cases had increased odds of reporting
reduced exercise tolerance which persisted after adjustment
for age and gender but partially attenuated after further
adjustment for weight (adjusted OR 2.58 [1.39, 4.78], p=
0.003). On examination, there was no objective evidence of
gait abnormality. However, after adjustment for age,
gender, menopause and weight, the odds of reporting a
previous joint replacement were the greater amongst cases
than controls–47 (13.2%) vs. 8 (4.0%), OR 2.69 (1.10,
6.60), p=0.031. After adjusting for age and gender, the
odds of reporting a history of cancer were similar amongst
cases and controls (OR 1.64 [0.84, 3.19], p=0.145).
When considering five cardinal features associated with
HBM after age and gender adjustment: (a) BMI >30, (b)
broad frame, (c) sinking when swimming, (d) mandible
enlargement on examination and (e) extra bone identifiable
on clinical examination, 70% of HBM cases had two or
more of these features, whilst 42% had four or more (18%
having all five), so that the positive predictive value of four
or more features was 78.0. When the frequency of clinical
features was compared between index cases vs. all relatives
and spouses combined, odds ratios were only partially
attenuated (Online Resource Table 3). Mean laboratory
values were similar between cases and controls, other than
HBM cases had a lower platelet count than controls (267.9
[260.1, 275.8] vs. 275.1 [264.4, 285.8], respectively, mean
difference 16.5 [3.6, 29.4]×109/L, p=0.012); platelet count
remained within the reference range in 95.3% of the study
population.
Other potential causes of raised BMD
In index cases with unexplained HBM, although no other
cause of HBM was evident from initial analysis of DXA
database scan images, this diagnosis was re-evaluated using
additional information provided by clinical history, exam-
ination, X-rays and blood tests. No HBM cases had the
clear dysmorphic features of previously reported extreme
skeletal dysplasias such as pycnodysostosis or Camurati–
Engelmann disease. Excessive oestrogen replacement
implant use has been associated with substantial increases
in BMD [24]. Eighteen female HBM cases reported
oestrogen replacement implant use of whom five had
affected first-degree relatives based upon the +3.2 Z-score
definition described above, suggesting a genetic basis to
their HBM. Three index cases gave a history of lithium
treatment (reported to increase BMD in mice [25]), two of
whom had relatives with HBM, whilst one did not. No
cases reported treatment with recombinant parathyroid
hormone or strontium ranelate. None of the index cases
who reported ever having fractured had radiological
features consistent with osteopetrosis [10] nor evidence
of pancytopenia. One HBM case had treated acromegaly,
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Table 4 The structural and symptomatic bone phenotype of high bone mass cases compared with unaffected relatives and spouses
n (555) HBM n
(%; n=355)
Control n
(%; n=200)
Unadjusted OR
(95% CI)
Unadjusted
p value
Adjusted OR
(95% CI)h
Adjusted
p valueh
The structural bone phenotype
Mandible enlargement 431 106 (37.9) 24 (15.9) 3.22 (1.96, 5.31) <0.001 4.16 (2.34, 7.39) <0.001
Broad frame 352 119 (55.9) 52 (37.4) 2.12 (1.37, 3.28) 0.001 3.55 (2.12, 5.95) <0.001
Shoe size (UK sizing)a 463 7.1 (6.9, 7.3) 7.9 (7.6, 8.2) −0.8 (−1.2, −0.4) <0.001 0.4 (0.1, 0.7) 0.009
Misshapen or extra bone reported 545 64 (18.2) 26 (13.4) 1.47 (0.88, 2.46) 0.137 1.77 (1.00, 3.14) 0.051
Misshapen or extra bone on examinationb 421 59 (21.6) 21 (14.2) 1.67 (0.97, 2.87) 0.066 2.07 (1.13, 3.78) 0.018
Torus palatinus and torus mandibularis 449 92 (31.5) 49 (31.2) 1.01 (0.67, 1.54) 0.949 1.50 (0.92, 2.44) 0.106
Dental overcrowding 483 93 (30.0) 60 (34.7) 0.81 (0.54, 1.20) 0.291 0.84 (0.53, 1.32) 0.447
Report of oral structural abnormalityc 546 29 (8.3) 10 (5.1) 1.69 (0.79, 3.61) 0.172 2.05 (0.89, 4.70) 0.091
Webbing of toes 391 13 (5.2) 6 (4.2) 1.25 (0.46, 3.36) 0.660 1.56 (0.50, 4.90) 0.442
Hammer toes 501 44 (13.4) 9 (5.2) 2.80 (1.33, 5.87) 0.007 2.17 (0.96, 4.91) 0.063
Carpal tunnel syndromed 555 21 (5.9) 5 (2.5) 2.56 (0.92, 7.07) 0.070 1.98 (0.69, 5.68) 0.203
Abnormal spine 408 106 (40.3) 35 (24.1) 2.12 (1.35, 3.34) 0.001 1.68 (0.99, 2.85) 0.053
Spinal kyphosis 501 25 (7.6) 10 (5.8) 1.33 (0.62, 2.84) 0.458 0.81 (0.34, 1.90) 0.627
Spinal scoliosis 501 19 (5.8) 3 (1.7) 3.47 (1.00, 12.05) 0.050 3.35 (0.87, 12.87) 0.078
Categories of buoyancy
Floats 517 171 (48.6) 143 (72.6) 1.00 <0.001 1.00 <0.001
Struggles to float 26 (7.4) 16 (8.1) 1.39 (0.69, 2.81) 1.93 (0.89, 4.19)
Sinks 116 (33)g 15 (7.6) 6.98 (3.77, 12.92) 7.11 (3.65, 13.84)
Unable to swim 19 (5.4) 11 (5.6) 1.45 (0.64, 3.28) 1.09 (0.42, 2.82)
Fracture history
Ever fractured 550 134 (38) 90 (45.7) 0.72 (0.50, 1.04) 0.080 1.03 (0.67, 1.56)i 0.908i
Fragility fracture 224 19 (14.2) 16 (17.8) 0.76 (0.37, 1.58) 0.468 0.56 (0.24, 1.29)i 0.173i
RTA-related fracture 224 12 (9.0) 5 (5.6) 1.67 (0.57, 4.92) 0.351 1.09 (0.30, 4.04)i 0.892i
Fracture after aged 45 541 40 (11.6) 17 (8.7) 1.38 (0.75, 2.54) 0.304 0.88 (0.43, 1.81)i 0.733i
Family history of fracture 499 150 (46.2) 97 (55.7) 0.68 (0.47, 0.99) 0.041 0.62 (0.41, 0.95) 0.027
The symptomatic bone phenotype
Mandible paine 550 39 (11.0) 6 (3.0) 4.29 (1.73, 10.63) 0.002 3.57 (1.37, 9.28) 0.009
Limb/bone painf 548 41 (11.6) 5 (2.6) 5.16 (1.98, 13.50) 0.001 5.06 (1.84, 13.88) 0.002
Joint pain 535 297 (86.6) 151 (78.6) 1.80 (1.11, 2.91) 0.017 1.04 (0.61, 1.79) 0.873
Skull pain, headaches or migraine 536 46 (13.4) 14 (7.3) 1.99 (1.05, 3.77) 0.036 2.04 (1.03, 4.03) 0.041
Reduced exercise tolerance 543 111 (31.8) 17 (8.8) 5.25 (2.94, 9.37) <0.001 3.30 (1.81, 6.04) <0.001
Abnormal gait 497 75 (23.0) 16 (9.4) 2.90 (1.62, 5.20) <0.001 1.39 (0.73, 2.65) 0.323
OR clustered odds ratio, CI confidence interval, RTA road traffic accident
a
Means and mean differences given for this continuous variable
b
Includes increased bone at sites of tendon and ligament insertion (tibial tuberosity, patella boarder, calcaneus at point of Achilles tendon, head of the fibula
and clavicle, olecranon, ulna styloid, radial head, navicular bone, MCP, PIP), bony swelling within ribs/costocartilage junctions, focal increases in bone
over the tibia and skull, global increases in skull size, prognatism, asymmetry of the mandible, chest wall, orbits and scapulae, including Sprengel’s and
Madelung’s deformities, camptodactyly, abnormally shaped patellae and pelvis, congenitally short digits, metacarpals and absent bone in toes
c
Oral structural abnormalities include eruption of extra sets of teeth, failure of eruption of adult teeth, persistent milk teeth into adulthood, eruption of teeth
through palate, convex palate, cleft palate, extra bone in mouth
d
Carpal tunnel syndrome reported or previously operated
e
Excluding isolated temporomandibular pain
f
Pain within bones, rather than pain within joints
g
Two HBM cases reported sinking in the Dead Sea despite the sea’s high specific gravity
h
Adjusted for age at recruitment, gender
i
Adjusted for age at recruitment, gender, years since menopause and oestrogen replacement use
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one myelofibrosis and one reported investigations for
possible ankylosing spondylitis. Three cases were identified
with serum phosphate level of <0.70 mmol/L and bridging
osteophytes of the lower thoracic and upper lumbar spine, of
whom one also had evidence of new bone formation at the
pelvis and upper femorae. Whilst radiological features were
consistent with diffuse idiopathic skeletal hyperostosis, in
combination with low phosphate, these may represent the
enthesopathy reported in X-linked hypophosphataemic rickets
[26], although other clinical features, such as short stature, a
family history or a history of fragility fractures, were absent.
Thus, in 20 individuals recruited with unexplained HBM,
more detailed clinical assessment gave a possible explanation
for their raised BMD, but analyses of clinical characteristics
were unchanged after their exclusion (Online Resource
Table 4), as were fracture analyses (data not shown).
Discussion
We found approximately 5 out of 1,000 NHS DXA scans
performed in England and Wales to have a T-/Z-score≥+4,
half of which were explained by artefactual elevations in
BMD resulting from osteoarthritic degeneration. Marked
elevations in DXA BMD are well recognised to arise from
a range of causes, including artefact where bone mass is not
truly increased [7]. However, to our knowledge, the relative
frequencies of these different causes have never previously
been reported. Our results suggest that, having excluded
approximately 50% of DXA scans with degenerative
artefactual increases in BMD, a known cause to explain
high BMD is only rarely present, with the majority of HBM
cases remaining unexplained, occurring at a prevalence of
approximately 2 out of 1,000 (a Z-score of ≥+4 would be
expected to occur 3 out of 100,000 times in a normally
distributed population [20]).
The UK NHS provides a unique opportunity for the
conduct of multi-centred observational studies of rare traits;
there are few countries in which a long-established, non-
commercial and national DXA service could be systematically
searched for an extreme of a normal distribution. Referral
indications, analysed in a subgroup, were typical of what
would be expected, for a population referred for routine DXA
scanning. With the exception of a lower proportion of repeat
scans, which would be expected as higher BMD does not
require monitoring, the DXA indications amongst high BMD
scans were broadly representative of the indications for all
scans. However, individuals who receive a DXA scanmay not
be representative of the general UK population, which limits
generalisability of our prevalence estimates.
We aimed to determine HBM status and the distribution of
BMD amongst relatives of HBM index cases. We found
relatives not to have a bi-modal distribution of BMD; bi-
modality would have been expected had HBM been caused by
a fully penetrant monogenic trait. However, approximately
40% of relatives had a BMD within the same range as HBM
index cases, consistent with a genetic cause underlying a
substantial proportion, though this does not differentiate
between monogenic and polygenic inheritance. Furthermore,
following categorisation of participants as cases or controls
based upon their BMD, we found evidence that HBM cases
were characterized by particular features suggestive of a mild
skeletal dysplasia which might be indicative of an underlying
monogenic disorder. For example, when compared to con-
trols, HBM cases tended to have a broad frame, enlarged
mandible, extra bone laid down at the site of tendon or
ligament insertions, dental abnormalities and larger shoe size
and vertebral area. Moreover, our finding that HBM cases had
difficulty floating when swimming is striking. There has been
one previous similar report in association with an LRP5
mutation [16], and whilst buoyancy has been suggested to
have a small influence on sprint swimming performance
[27], to our knowledge negative buoyancy has not been
reported as a feature of any other clinical condition. In
contrast, no increase in pathological features such as cranial
nerve palsies were identified, such as in sclerosteosis and
Van Buchem’s disease [8, 9]. Taken together, the constella-
tion of mildly dysmorphic features, along with a high
frequency of HBM in relatives, suggests that an appreciable
proportion of patients found to have unexplained HBM after
routine bone densitometry have an albeit mild form of
skeletal dysplasia.
Our description of relatively benign familial HBM, without
severe pathological features related to cranial nerve compres-
sion, most closely resembles the initial case reports of
autosomal dominant activating mutations in LRP5, character-
ized by large mandibles and floating difficulty, whereas
pathological features such as cranial nerve palsies are
generally lacking [13, 16]. Reports have suggested such
cases are resistant to fractures despite exposure to heavy
trauma such as road traffic accident [12]. However, a
reduced risk of fracture was not detected amongst our
HBM cases. Heterozygous carriers of sclerosteosis, who are
clinically unremarkable, have been found to have raised
BMD Z-scores between +0.4 and +5.2 [28]. However, direct
sequencing of our HBM cases for mutations affecting exons
2, 3 and 4 of LRP5 and the entire coding region of SOST
have thus far identified causative mutations in <2% of
subjects [29]. Whilst many subjects found to have asymp-
tomatic HBM following routine bone densitometry may
harbour a mild skeletal dysplasia, in the great majority of
cases, the genetic basis remains unknown.
Several other features were also associated with HBM.
HBM cases had increased bone-related pains at several
sites, in both unadjusted and adjusted models, which was
unexplained. We had speculated HBM cases might have an
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increased risk of OA, on the basis that pathways implicated
in HBM may also contribute to OA [13, 18, 19]. Reported
joint pain was no higher in HBM cases, after adjusting for
important confounders, and these cases had no objective
evidence of abnormal gait. However, HBM cases were
more likely to report a history of joint replacement surgery;
this association persisted after adjustment for age, gender,
menopausal status and weight. Joint replacement surgery is
arguably the most specific of these indicators for OA.
Although HBM cases were more likely to report reduced
exercise tolerance, multiple regression analyses suggested that
this association was explained by increased weight, rather
thanmusculoskeletal pathology. Interestingly, HBM cases had
a lower mean platelet count than controls; although the
difference was relatively small and could have arisen by
chance, it is interesting to note that platelet dysfunction has
been linked to raised bone mass through the RANKL/OPG
pathway in Ghosal syndrome [30] and B-integrins in mice
models [31] and one infant [32]. Finally, HBM cases had a
greater BMI, which as far as we are aware has not previously
been reported in this context [12, 15]. The proportions of this
BMI difference explained by fat, lean and bone mineral mass
remain to be determined. Gains in fat mass may reduce
validity of DXA measures [33, 34], with obesity potentially
leading to misclassification of HBM status. If BMD was
overestimated in individuals with greater fat mass, the latter
may have been over-represented in the recruited population,
explaining the observed BMI association.
In terms of study weaknesses, our use of relatives to
provide both cases and controls to analyses examining
clinical characteristics is likely to have underestimated
differences (than had cases been compared with general
population controls), due to shared genetic factors, partic-
ularly as we had to apply an arbitrary Z-score threshold to a
continuous BMD distribution to assign case and control
status. However, the fact that albeit partially attenuated
differences were seen in further analyses, comparing index
cases to relatives and spouses combined, suggests that the
precise threshold used to separate relatives into cases and
controls had little impact on the overall findings. Our HBM
definition threshold will still have included some individ-
uals with co-morbid lumbar OA. Our analysis strategy,
clustering by family, endeavours to take account of over-
representation of features common within larger families.
Our study design most likely accounts for differences
observed between cases and controls in terms of age,
gender, post-menopausal status and oestrogen treatment
use, given the gender and age biases inherent in those
referred to NHS DXA services. For example, index cases
were more often female and their relationships heterosex-
ual, so partner controls were more often male. That more
female relatives were recruited may be explained by
differential employment restrictions on clinic attendance
or greater awareness of bone disease issues such, as
osteoporosis, amongst women. As index cases were more
often post-menopausal, their children rather than their
parents were more likely to participate, explaining the age
difference between cases and controls.
Overall, low response rates reduce generalisability and
increase the possibility of non-response bias. Large epide-
miological studies report response rates of approximately
60% [35, 36]. At first glance, our index case response rate
of 50% (from one letter and one telephone call if a contact
number was available), appears relatively low. However,
since some DXA scans had been performed up to nearly
20 years earlier, more non-responders may have died or
moved away of which we were unaware. Attempts were
made to limit participation bias by offering home visits to
less mobile individuals and telephone consultations to those
busy with work or who had logistical limitations. Reassur-
ingly no systematic differences between index case res-
ponders and non-responders were detected. The response
rates of 26% and 28% amongst relatives and spouses were
of more concern; the study design relied upon index cases
passing on invitations and did not enable us to re-invite or
telephone relatives or spouses directly. This low response
rate may reflect participation bias, whereby responders may
suspect they have HBM themselves, or wish to have a DXA
performed for a variety of health agendas. Our finding that
three spouses fulfilled HBM index case criteria (4.9%,
rather than the approximately 0.2% amongst individuals
having a DXA scan) is consistent with assortative mating;
as exemplified by height, tall people generally partner other
tall people [37]; larger-framed individuals may well behave
similarly. Assortative mating may explain the elevated
mean Z-score amongst unaffected spouses. We attempted
to limit observer and recall biases from doctors/nurses and
relatives/spouses, respectively, by collecting clinical data
prior to performing a DXA scan. At the time of the study,
all DXA machines used fan-beam technology; however, a
minority of historical DXA scans searched were acquired
on earlier pencil-beam machines; consequent measurement
differences in bone area, whilst reported to be small [38],
were not accounted for in this study.
In conclusion, we have examined the prevalence and
clinical characteristics of unexplained HBM, following a
systematic analysis of patients who underwent DXA
scanning at 15 centres in England and Wales. We found
that approximately 1 out of 200 individuals undergoing a
DXA scan had a BMD T- and/or Z-score at the lumbar
spine or hip of ≥+4.0. Whilst approximately 50% of these
had artefactually elevated BMD due to degenerative
changes, the majority of the remainder had a true,
unexplained increase in BMD. Interestingly, this latter
group appears mainly to comprise individuals with a mild
skeletal dysplasia, as nearly 40% of first-degree relatives
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were affected and clinical features of mild skeletal dys-
morphism such as a broad frame, mandible enlargement
and difficulty floating were frequently seen. Significant
pathological features reported in more severe forms of
skeletal dysplasia, such as cranial nerve palsies, were not
observed. However, other features were associated with
HBM which had not been expected, such as an increased
BMI, more frequent bone pain, reduced exercise tolerance
and marginally lower platelet levels. Further studies are
underway to examine the phenotype of unexplained HBM
in more detail. HBM appears to be identifiable from clinical
features but unexplained by known LRP5 and SOST
mutations. Understanding of the genetic basis of this unique
population of individuals offers a novel opportunity to
provide new insights into the genetic control of bone mass
and its related characteristics.
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